Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Guided Therapeutics (GTHP) Common Equity (2016 - 2025)

Guided Therapeutics' Common Equity history spans 16 years, with the latest figure at -$6.0 million for Q4 2025.

  • On a quarterly basis, Common Equity fell 22.72% to -$6.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$6.0 million, a 22.72% decrease, with the full-year FY2025 number at -$6.0 million, down 22.72% from a year prior.
  • Common Equity hit -$6.0 million in Q4 2025 for Guided Therapeutics, down from -$5.7 million in the prior quarter.
  • Over the last five years, Common Equity for GTHP hit a ceiling of -$2.7 million in Q3 2022 and a floor of -$8.0 million in Q1 2021.
  • Historically, Common Equity has averaged -$5.0 million across 5 years, with a median of -$5.0 million in 2022.
  • Biggest five-year swings in Common Equity: skyrocketed 65.78% in 2022 and later tumbled 40.78% in 2024.
  • Tracing GTHP's Common Equity over 5 years: stood at -$5.4 million in 2021, then skyrocketed by 47.05% to -$2.9 million in 2022, then tumbled by 32.02% to -$3.8 million in 2023, then decreased by 28.46% to -$4.9 million in 2024, then decreased by 22.72% to -$6.0 million in 2025.
  • Business Quant data shows Common Equity for GTHP at -$6.0 million in Q4 2025, -$5.7 million in Q3 2025, and -$5.5 million in Q2 2025.